Gastrointestinal mucormycosis complicated by arterio-enteric fistula in a patient with non-Hodgkin's lymphoma.
Gastrointestinal mucormycosis is a rare, often fatal, systemic infection found predominantly in immunocompromised patients. We report a case of gastrointestinal mucormycosis in a 53-year-old female with non-Hodgkin's lymphoma. Following her first course of chemotherapy, bowel obstruction developed as a result of mucormycosis. Despite treatment with antifungal therapy, she required a laparotomy owing to severe haemorrhage caused by mucormycosal invasion of her iliac artery. With continued antifungal treatment and further chemotherapy, she ultimately underwent reversal of her Hartmann's procedure and remains disease-free.
Mir
N
N
Department of Haematology, Lewisham Hospital, The Lewisham Hospital NHS Trust, Lewisham High Street, London, UK.
Edmonson
R
R
Yeghen
T
T
Rashid
H
H
D000666:Amphotericin B / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000382:microbiology* / Q000628:therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D006470:Hemorrhage / Q000209:etiology / Q000601:surgery; D006801:Humans; D007083:Iliac Artery / Q000473:pathology / Q000601:surgery; D016867:Immunocompromised Host; D007412:Intestinal Fistula / Q000382:microbiology / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D008875:Middle Aged; D009091:Mucormycosis / Q000150:complications* / Q000209:etiology* / Q000628:therapy; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D016157:Vascular Fistula / Q000382:microbiology / Q000628:therapy*; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014750:Vincristine; D000666:Amphotericin B; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide; D011239:Prednisolone